Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 4 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Results 1 - 20 of 346 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar gunngun (< 20) Submitted: 10/21/2014 6:02:05 AM : Underperform Start Price: $104.05 GILD Score: +0.12

It's gone up too much too fast and is due for a sizable correction.

Recs

0
Member Avatar Tophinater (< 20) Submitted: 10/20/2014 3:32:42 PM : Outperform Start Price: $102.07 GILD Score: +0.98

><)));'>

Recs

0
Member Avatar tradeseeker14 (41.35) Submitted: 10/20/2014 12:56:33 PM : Underperform Start Price: $102.25 GILD Score: -0.28

Looks way over owned ripe for nice correction

Recs

0
Member Avatar roger55 (< 20) Submitted: 10/19/2014 3:25:46 AM : Outperform Start Price: $101.15 GILD Score: +0.86

have new drug approved by fda

Recs

0
Member Avatar jlstachura (< 20) Submitted: 10/18/2014 3:39:05 PM : Outperform Start Price: $101.15 GILD Score: +0.86

Gild has a lead and no one has yet caught up

Recs

0
Member Avatar Sceaj (< 20) Submitted: 10/13/2014 10:15:07 AM : Outperform Start Price: $101.92 GILD Score: +0.87

Hep "C" drug - approved for Medicaid patients. That's huge.

Recs

0
Member Avatar PLocklar (22.94) Submitted: 10/12/2014 5:19:45 PM : Outperform Start Price: $104.49 GILD Score: -1.18

outperform

Recs

0
Member Avatar SegaRob (< 20) Submitted: 10/3/2014 1:03:42 PM : Outperform Start Price: $106.79 GILD Score: -0.18

Gilead's Hep C treatment is "top dog" and "first mover." Sofosbuvir (sovaldi) is a big hit and the new combo pill with Ledipasvir will be first all-oral and first interferon-free regimen for HCV. Moreover, it shows efficacy in all HCV genotypes. This is a huge potential! Also they have a successful portfolio of other drugs and track record making new drugs that will spur furtue growth. I am expecting EPS $8-10 in next year or so. Even with the big run this year, using a forward P/E ratio of 20, I think there's a good chance the stock could double in a few years or less from current prices under $107.

Recs

0
Member Avatar billney (< 20) Submitted: 10/2/2014 6:28:31 PM : Outperform Start Price: $103.42 GILD Score: +2.08

Rising Earning, Rising Value, Rising Price.

Recs

0
Member Avatar boomertom (33.65) Submitted: 9/30/2014 2:45:27 PM : Outperform Start Price: $106.22 GILD Score: +0.63

Superb company. Grossly undervalued.

Recs

0
Member Avatar qualityplustime (< 20) Submitted: 9/30/2014 2:12:57 AM : Outperform Start Price: $107.48 GILD Score: -0.27

GILD has begun to license Sovaldi (Hepititis C blockbuster) for sale in India and other large markets, I believe the earnings multiple will expand in Q4.

Recs

0
Member Avatar Googlespooch (20.63) Submitted: 9/29/2014 12:15:01 AM : Outperform Start Price: $107.59 GILD Score: -1.10

Strong HIV and Hep C portfolio. Impressive margins and growth prospects.

Recs

0
Member Avatar RugbyViking13 (86.01) Submitted: 9/27/2014 5:27:57 PM : Outperform Start Price: $107.59 GILD Score: -1.10

they make drugs that make money. Probably late to this party

Recs

0
Member Avatar Irish2014 (59.51) Submitted: 9/13/2014 9:23:38 AM : Outperform Start Price: $101.90 GILD Score: +5.76

Outperform due to Sovaldi utilization and other pipeline/expansion opportunities.

Recs

0
Member Avatar Morass (63.20) Submitted: 9/6/2014 9:14:03 PM : Outperform Start Price: $104.95 GILD Score: +3.63

GILD is a proven leader in biotech.

Recs

0
Member Avatar HILL6BILLY (< 20) Submitted: 9/5/2014 4:45:34 PM : Outperform Start Price: $104.95 GILD Score: +3.63

Earnings almost too good to be true......

Recs

0
Member Avatar calguy489 (< 20) Submitted: 9/2/2014 10:26:29 AM : Outperform Start Price: $108.47 GILD Score: +0.32

Great products

Recs

0
Member Avatar cipo (< 20) Submitted: 8/28/2014 9:56:02 AM : Outperform Start Price: $107.88 GILD Score: +0.39

the growth of free cash flow could lead to a successful dividend policy

Recs

0
Member Avatar irondistance (< 20) Submitted: 8/25/2014 3:30:51 PM : Outperform Start Price: $107.20 GILD Score: +1.18

SOVALDI

Recs

0
Member Avatar Stigshift (< 20) Submitted: 8/22/2014 3:26:17 PM : Outperform Start Price: $74.85 GILD Score: +36.46

real money pick

Featured Broker Partners


Advertisement